TScan Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Revenue	21.05	13.54	10.14	1.09	0
Revenue Growth (YoY)	55.52%	33.47%	834.65%	-	-
Gross Profit	21.05	13.54	10.14	1.09	0
Selling, General & Admin	26.35	20.35	13.83	6.74	4.77
Research & Development	88.15	59.82	44.95	20.58	9.44
Operating Expenses	114.51	80.17	58.78	27.32	14.21
Operating Income	-93.46	-66.64	-48.64	-26.23	-14.21
Interest Expense / Income	3.76	1.18	0	0	0
Other Expense / Income	-8	-1.59	-0.02	-0.11	-0.55
Pretax Income	-89.22	-66.22	-48.63	-26.13	-13.66
Net Income	-89.22	-66.22	-48.63	-26.13	-13.66
Shares Outstanding (Basic)	66	24	12	1	0
Shares Outstanding (Diluted)	66	24	12	1	0
Shares Change	172.78%	106.20%	1173.20%	137.87%	-
EPS (Basic)	-1.36	-2.75	-4.17	-28.52	-35.47
EPS (Diluted)	-1.36	-2.75	-4.17	-28.52	-35.47
Free Cash Flow	-64.5	-70.73	-58.62	-7.26	-13.77
Free Cash Flow Per Share	-0.98	-2.94	-5.03	-7.93	-35.76
Gross Margin	100.00%	100.00%	100.00%	100.00%	-
Operating Margin	-444.00%	-492.32%	-479.65%	-2417.79%	-
Profit Margin	-423.86%	-489.26%	-479.49%	-2408.02%	-
Free Cash Flow Margin	-306.45%	-522.56%	-578.03%	-669.22%	-
EBITDA	-80.1	-59.91	-45.3	-24.9	-13.14
EBITDA Margin	-380.53%	-442.62%	-446.67%	-2294.65%	-
Depreciation & Amortization	5.36	5.14	3.33	1.23	0.52
EBIT	-85.46	-65.05	-48.63	-26.13	-13.66
EBIT Margin	-406.00%	-480.57%	-479.49%	-2408.02%	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).